Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Go back to Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 67.10 -1.26 (1.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.36 | 52 Week High | $19.98 | |||
| Open | $68.00 | 52 Week Low | $10.52 | |||
| Day High | $69.09 | P/E | N/A | |||
| Day Low | $66.98 | EPS | $-1.45 | |||
| Volume | 2,806,723 | |||||
